Answers are grounded in this paper and cite their sources.
Unraveling the risk patterns of pharmaceutical transformation products (TPs) in estuaries is critical yet challenging, largely due to poorly understood mechanisms by which hydrology and physicochemical drivers jointly govern their fate. Here, we investigated pharmaceutical contaminants and their environmental drivers across 23 sites in the Pearl River Estuary during both dry and wet seasons, using high-resolution mass-spectrometry-based nontarget screening. A total of 99 pharmaceuticals and 57 TPs were identified. To the best of our knowledge, 45 of these substances were not previously reported in estuarine waters. The total concentration of pharmaceuticals and TPs was higher in the dry season (172–1244 ng/L) than in the wet season (35.8–477 ng/L). The overall distribution characteristics of pharmaceuticals were best explained by the combined effects of hydrodynamic dilution, enhanced environmental attenuation, and rainfall-triggered non-point source inputs driven by macroscopic hydrometeorological shifts, as evidenced by seven identified season-discriminating marker compounds. At the micro-scale, salinity and dissolved oxygen were strongly associated with the observed pharmaceutical transformation. Ecological risk assessment revealed that while parent pharmaceuticals generally drove the overall risk, TPs played a disproportionately prominent role for specific therapeutic classes. Notably, TPs of cardiovascular drugs accounted for 94% of the class-specific risk in the dry season. Our findings highlight the need to incorporate environmental drivers and class-specific TPs into future monitoring and regulatory strategies to mitigate estuarine ecological risks.
No takes yet. Share an insight, caveat, or question.
Ai et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: